A5038519757- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
- Acute Ischemic Stroke Management
- Coronary Interventions and Diagnostics
- Vascular Procedures and Complications
- Diabetes Treatment and Management
- Heart Failure Treatment and Management
- Lipoproteins and Cardiovascular Health
- Heparin-Induced Thrombocytopenia and Thrombosis
- Diabetes Management and Research
- Cardiac Imaging and Diagnostics
- Healthcare cost, quality, practices
- Cardiac Arrest and Resuscitation
- Blood Pressure and Hypertension Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Ultrasound in Clinical Applications
- Health Promotion and Cardiovascular Prevention
- Central Venous Catheters and Hemodialysis
- Chronic Kidney Disease and Diabetes
- Chronic Disease Management Strategies
- Metabolism, Diabetes, and Cancer
- Cardiovascular Function and Risk Factors
Umeå University
2013-2025
Östersunds Hospital
2014-2024
Skaraborg Hospital
2014
Karolinska Institutet
2014
The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use radial-artery access for PCI and administration potent P2Y12 inhibitors without planned glycoprotein IIb/IIIa inhibitors.In this multicenter, randomized, registry-based, open-label clinical trial, we enrolled either ST-segment elevation...
Pretreatment of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) P2Y12 receptor antagonists is a common practice despite the lack definite evidence for its benefit.To investigate association antagonist pretreatment vs no mortality, stent thrombosis, and in-hospital bleeding in NSTE-ACS undergoing percutaneous intervention (PCI).This cohort study used prospective data from Swedish Coronary Angiography Angioplasty Registry 64 857 who underwent procedures between 2010...
Abstract Aims To compare coronary artery bypass grafting (CABG) and percutaneous intervention (PCI) for treatment of patients with heart failure due to ischaemic disease. Methods results We analysed all-cause mortality following CABG or PCI in reduced ejection fraction multivessel disease (coronary stenosis >50% ≥2 vessels left main) who underwent angiography between 2000 2018 Sweden. used a propensity score-adjusted logistic Cox proportional-hazards regressions instrumental variable...
Most reports on the declining incidence of myocardial infarction (MI) during COVID-19 have either been anecdotal, survey results or geographically limited to areas with lockdowns. We examined MI pandemic in Sweden, which has remained an open society a different public health approach fighting COVID-19.We assessed rate (IR) as well ratios (IRRs) all referred for coronary angiography Sweden using nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR), (1 March 2020-7 May...
Ischemic stroke after acute myocardial infarction is an important complication. It unknown whether the risk has changed because treatment of improved during past decade. There also conflicting data about predictors risk.To obtain 1-year incidence infarction, Register Information and Knowledge Swedish Heart Intensive Care Admissions database for years 1998 to 2008 was merged with National Patient (NPR). The time trend studied by dividing entire period into 5 separate periods. Independent were...
Background and Purpose— Acute myocardial infarction (AMI) increases the risk of ischemic stroke, mortality among these patients is high. Here, we aimed to estimate 1-year reliably after AMI complicated by stroke. We also identify trends over time for during 1998–2008, as well factors that predicted increased or decreased mortality. Methods— Data 173 233 unselected with were collected from Swedish Register Information Knowledge about Heart Intensive Care Admissions registry 1998–2008....
Abstract There is limited data on long-term outcomes after hospitalization for ACS. We aimed to estimate the rate of recurrent cardiovascular events in long-term, a population-based, unselected cohort ACS patients. included 1379 patients with hospitalized at Östersund hospital 2010–2014 and followed them from day discharge 31 December 2017. The primary endpoint was unadjusted composite CV death, AMI ischemic stroke. Risk factors were assessed multivariable Cox proportional hazards regression...
Abstract Data are scarce on long-term outcomes after ischemic stroke (IS) or transient attack (TIA). In this prospective cohort study, we examined the cumulative incidence of major adverse cardiovascular events (MACE) IS and TIA using a competing risk model factors associated with new Cox-proportional hazard regression model. All patients discharged alive from Östersund Hospital between 2010 2013 (n = 1535) were followed until 31 December 2017. The primary endpoint was composite IS, type 1...
Objectives The purpose of this observational study was to evaluate the effects radial artery access versus femoral on risk 30-day mortality, inhospital bleeding and cardiogenic shock in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods We used data from SWEDEHEART registry included all who were treated intervention Sweden between 2005 2016. compared had by regard endpoint all-cause death within 30 days, using a multilevel...
Background: Bivalirudin was not superior to unfractionated heparin in patients with myocardial infarction (MI) treated percutaneous coronary intervention and no planned use of GPI (glycoprotein IIb/IIIa inhibitors) contemporary clinical practice radial access potent P2Y 12 -inhibitors the VALIDATE-SWEDEHEART randomized trial (Bivalirudin Versus Heparin STEMI NSTEMI Patients on Modern Antiplatelet Therapy–Swedish Web-System for Enhancement Development Evidence-Based Care Heart Disease...
Secondary prevention after acute coronary syndrome (ACS) is essential to reduce morbidity and mortality, but related studies have been fairly small or performed as clinical trials with non-representative patient selection. Long-term follow-up data are also minimal. A nurse-led for risk factor improvement may be effective, the evidence limited.The aims of this study perform an adequately sized, nurse-led, long-term secondary preventive inclusion unselected population ACS patients. The focus...
Background: The optimal anti-coagulation strategy for patients with non-ST-elevation myocardial infarction treated percutaneous coronary intervention is unclear in contemporary clinical practice of radial access and potent P2Y12-inhibitors. aim this study was to investigate whether bivalirudin superior heparin monotherapy without routine glycoprotein IIb/IIIa inhibitor use. Methods: In a large pre-specified subgroup the multicentre, prospective, randomised, registry-based, open-label...
Aims It is unknown whether dual antiplatelet therapy with ticagrelor instead of clopidogrel reduces the risk ischaemic stroke in acute myocardial infarction patients that undergo percutaneous coronary intervention. This study investigated introduction was associated reduced a real-world population. Methods and results Patients after from 8 December 2009–31 2013 were identified using Register for Information Knowledge on Swedish Heart Intensive Care Admissions National Patient Register. The...
In the Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarction Patients on Modern Antiplatelet Therapy Swedish Web System for Enhancement Development of Evidence-based Care Heart Disease Evaluated according to Recommended Therapies Registry Trial (VALIDATE-SWEDEHEART), bivalirudin was not superior unfractionated heparin patients with acute coronary syndrome undergoing invasive management. We assessed whether access site had an impact primary endpoint...
Enhanced follow-up is needed to improve the results of secondary preventive care in patients with established cardiovascular disease. We examined effect long-term, nurse-based, by telephone on recurrence events. Open, randomised, controlled trial two parallel groups. Between 1 January 2010 and 31 December 2014, consecutive (n = 1890) admitted hospital due stroke, transient ischaemic attack (TIA), or acute coronary syndrome (ACS) were included. Participants randomised (1:1) nurse-based...
Abstract Progress in decreasing ischemic complications acute coronary syndrome (ACS) has come at the expense of increased bleeding risk. We estimated long-term, post-discharge incidence serious bleeding, characterized type, and identified predictors its impact on mortality an unselected cohort patients with ACS. In this population-based study, we included 1379 ACS, 2010–2014. Serious was defined as intracranial hemorrhage (ICH), requiring hospital admission, or transfusion surgery. During a...
To evaluate the impact of a rapid change in preferred treatment from clopidogrel to ticagrelor on risk ischemic stroke following acute myocardial infarction (AMI). Data for AMI patients treated with either or were obtained Swedish Register Information and Knowledge about Heart Intensive Care Admissions (RIKS-HIA). Patients divided into two cohorts, each covering two-year time period; initial prescription (20 Dec 2011) was used as cut-off point. early cohort (n = 23,447) clopidogrel, while...
Abstract IntroductionThere is limited data on long-term outcomes after hospitalization for ACS. We aimed to estimate the rate of recurrent cardiovascular events in long-term, a population-based, unselected cohort ACS patients.Methods and resultsWe included 1379 patients with hospitalized at Östersund hospital 2010-2014 followed them from day discharge 31 December 2017. The primary endpoint was unadjusted composite CV death, AMI ischemic stroke. Risk factors were assessed multivariable Cox...